← Eichor
Study identifier: NCT05178069 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

LGG Supplementation in Patients With AUD and ALD

Condition: Alcohol Use Disorder · Alcohol-associated Liver Disease  ·  Sponsor: University of Louisville

PhasePhase 2
Planned participants60
Who can joinAll sexes, 21 Years to 65 Years
Healthy volunteersNo

About this study

To test the efficacy of 6-month LGG compared to placebo in treating Alcoholic Use Disorder (AUD) and liver injury in Alcoholic Hepatitis (AH). And to evaluate the effects of LGG treatment compared to placebo on therapeutic-mechanistic markers of the gut-brain axis and pro-inflammatory activity in patients with AUD and moderate AH

This description comes directly from the study's public registry record.

Talk to the study team

Amber Jackson, BS CCRP  ·  502-852-2905  ·  amber.jackson.1@louisville.edu

Steve Mahanes  ·  502-852-1388  ·  steve.mahanes@louisville.edu

Always discuss trial participation with your own doctor first.

Locations (1)

University of Louisville HospitalLouisville, Kentucky, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05178069